

Comprehensive genomic and tailored biomarker insights for optimal therapy selection in a single order

Cancer type	Add-on testing
Biliary/Cholangiocarcinoma	CLDN18.2, HER2 CDx, PD-L1 CDx (22C3)
Bladder	HER2 CDx, PD-L1 (22C3)
Breast	AR, ER, HER2 CDx, Ki-67, PD-L1 CDx (22C3), PR
Cervical	HER2 CDx, PD-L1 CDx (22C3)
Colorectal	HER2 CDx
Endometrial/Uterine carcinoma	ER, HER2 CDx, p53, PD-L1 (22C3), PR
Esophageal adenocarcinoma (EAC)	CLDN18.2 CDx, HER2 CDx, PD-L1 CDx (22C3), PD-L1 CDx (28-8)
Esophageal squamous cell carcinoma (ESCC)	PD-L1 CDx (22C3)
Gastric/GEJ	CLDN18.2 CDx, HER2 CDx, PD-L1 CDx (22C3), PD-L1 CDx (28-8)
Head and neck squamous cell carcinoma (HNSCC)	HER2 CDx, PD-L1 CDx (22C3), HPV RNA ISH Panel
Hepatocellular carcinoma	HER2 CDx, PD-L1 (22C3)
Melanoma	PD-L1 (22C3)
Non-small cell lung cancer (NSCLC)*	ALK CDx, c-MET CDx, HER2 CDx, PD-L1 CDx (22C3), PD-L1 CDx (SP142), ROS1
Ovarian/Fallopian/Peritoneal	ER, FOLR1 CDx, HER2 CDx, PD-L1 CDx (22C3), PR, HRD [†] through NGS-based scoring
Pancreatic	CLDN18.2, HER2 CDx, PD-L1 (22C3)
Prostate	AR, HER2 CDx, PD-L1 (22C3)
Renal/Renal Cell Carcinoma (RCC)	HER2 CDx, PD-L1 (22C3)
Sarcoma/GIST	HER2 CDx, PD-L1 (22C3)
Thyroid	HER2 CDx, PD-L1 (22C3)
Cancer of unknown primary (CUP)	AR, ER, HER2 CDx, PD-L1 (22C3), PR
Other	PD-L1 (22C3)

HER2 FISH reflex will occur for resulted 2+ equivocal IHC results.
If selected with order, PanTracer LBx will be added as a reflex if tissue testing is not possible or fails.

*PD-L1 CDx 28-8 and PD-L1 CDx SP263 are available to add to NSCLC cases by request.
[†]HRD scoring is validated for primary epithelial ovarian tumors only and is not available to New York State clients.

CDx = companion diagnostic
FISH = fluorescence in situ hybridization; GEJ = gastroesophageal junction; GIST = gastrointestinal stromal tumor; HPV = human papillomavirus;
HRD = homologous recombination deficiency; IHC = immunohistochemistry; ISH = in situ hybridization; NGS = next-generation sequencing.

NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and oncology data solutions. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with innovative diagnostic and predictive testing to help them diagnose and treat cancer. Headquartered in Fort Myers, FL, NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories for full-service sample processing and analysis services throughout the US and a CAP-accredited full-service, sample-processing laboratory in Cambridge, England, United Kingdom. ©2026 NeoGenomics Laboratories, Inc. All rights reserved.